Search

Copyright of Ginecologia.ro is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Gangliogliomas are extremely rare central nervous tumors composed of an admixture of glial and neuroepithelial elements. Gangliogliomas mainly affect the temporal lobe and occur in the pediatric population. There are several controversies in the scientific literature regarding these tumors, which debuted with the exclusion of grade II gangliogliomas in the 2006 edition of the current World Health Organization (WHO) classification. The upcoming edition due in the last months of 2021 is not expected to include changes regarding the current classification of glio-neuronal tumors. This vision has led to a number of articles that have pushed for the reintroduction of this category. However, these articles support the reintroduction of this degree in terms of prognosis and evolution, without providing clear criteria for the inclusion of certain gangliogliomas in this category. On the other hand, there are uncertainties about the relationship of gangliogliomas with focal cortical dysplasia. The coexistence of the two entities, as well as their succession are occasionally encountered in practice and have led to numerous studies that have tried to clarify the relationship between them. The most common and most accessible element in routine practice is the immunoreactivity for CD34. Both entities express this marker, and dual lesions express the highest percentage of immunoreactivity for CD34. In this article, we study the expression of CD34 on a series of cases including both grade I gangliogliomas and anaplastic gangliogliomas diagnosed between 2011 and 2020 in a Neuropathology Unit in Bucharest Romania. [ABSTRACT FROM AUTHOR]

On the 2nd of December 2003, in the Official Journal of the European Union it was published the “Council Recommendation on cancer screening” which had issued recommendations, setting out principles of best practice in the early detection of cancer. The recommendations called on all EU countries to take a common action to implement national, population-based screening pro-grams for breast, cervical and colorectal cancer, as an in te gral part of the Community Agreement duties in or der to complete the national policies, with the aim to im prove the public health. A first report, published in 2008, showed that, despite the documented progress, the mem ber states had fallen short of the established target set for the minimum number of examinations by more than 50%. The second report, consisting in the European Coun cil’s recommendations implementation concerning can cer screening, was elaborated and published in 2017, with the attendance of 28 member states. In a subsequent re port regarding the European Council’s recommendations im-ple men ta tion status, Romania appears in the minority of EU member states that do not have yet organized po pu la-tion-screening programs for breast cancer and colorectal can cer. In 2020, Romania declared a 0.2% coverage rate of breast examination, an inviting rate of 0.2%, and an 82% participation rate for breast cancer screening. Re gar ding cervical cancer screening, the coverage rate is 9.2%, the inviting rate is 65% and the participation rate is 14.2%. The general intent of European Union’s plan to com bat can cer subsides in the prevention, detection and treat-ment improvement, as well as cancer management in the EU, reducing health inequalities between and inside the member states. The technical support offered to the mem ber states could contribute to the increase of screening rates, while guides and structural support could contribute to assuring a comparably high health system quality in all Europe. [ABSTRACT FROM AUTHOR]

Copyright of Ginecologia.ro is the property of MEDICHUB MEDIA, S.R.L. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)